AdAlta Ltd. ( (AU:1AD) ) has shared an update.
AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, offering new shares at a 51% discount to the 15-day VWAP. The funds will support the company’s business development and strategic evaluations, enhancing its positioning in the biotechnology sector. The rights issue is partially underwritten and aims to provide shareholders with additional options, reflecting AdAlta’s commitment to unlocking shareholder value.
More about AdAlta Ltd.
AdAlta Limited is a biotechnology company based in Australia, focusing on the development of innovative immunotherapy solutions, particularly through its ‘East to West’ cellular immunotherapy strategy. The company is engaged in advancing its CAR-T in-licensing agreements and exploring strategic options for its assets.
YTD Price Performance: -50.0%
Average Trading Volume: 589,626
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.22M
Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.